112 related articles for article (PubMed ID: 12171518)
1. Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Metcalf CA; van Schravendijk MR; Dalgarno DC; Sawyer TK
Curr Pharm Des; 2002; 8(23):2049-75. PubMed ID: 12171518
[TBL] [Abstract][Full Text] [Related]
2. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents.
Vu CB; Luke GP; Kawahata N; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keenan TP; Pradeepan S; Corpuz E; Merry T; Bohacek RS; Dalgarno DC; Narula SS; van Schravendijk MR; Ram MK; Adams S; Liou S; Keats JA; Violette SM; Guan W; Weigele M; Sawyer TK
Bioorg Med Chem Lett; 2003 Sep; 13(18):3071-4. PubMed ID: 12941336
[TBL] [Abstract][Full Text] [Related]
6. Src inhibitors: genomics to therapeutics.
Sawyer T; Boyce B; Dalgarno D; Iuliucci J
Expert Opin Investig Drugs; 2001 Jul; 10(7):1327-44. PubMed ID: 11772255
[TBL] [Abstract][Full Text] [Related]
7. Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Wang Y; Metcalf CA; Shakespeare WC; Sundaramoorthi R; Keenan TP; Bohacek RS; van Schravendijk MR; Violette SM; Narula SS; Dalgarno DC; Haraldson C; Keats J; Liou S; Mani U; Pradeepan S; Ram M; Adams S; Weigele M; Sawyer TK
Bioorg Med Chem Lett; 2003 Sep; 13(18):3067-70. PubMed ID: 12941335
[TBL] [Abstract][Full Text] [Related]
8. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.
Violette SM; Shakespeare WC; Bartlett C; Guan W; Smith JA; Rickles RJ; Bohacek RS; Holt DA; Baron R; Sawyer TK
Chem Biol; 2000 Mar; 7(3):225-35. PubMed ID: 10712930
[TBL] [Abstract][Full Text] [Related]
9. Progress in the development of inhibitors of SH2 domains.
Cody WL; Lin Z; Panek RL; Rose DW; Rubin JR
Curr Pharm Des; 2000 Jan; 6(1):59-98. PubMed ID: 10637372
[TBL] [Abstract][Full Text] [Related]
10. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.
Violette SM; Guan W; Bartlett C; Smith JA; Bardelay C; Antoine E; Rickles RJ; Mandine E; van Schravendijk MR; Adams SE; Lynch BA; Shakespeare WC; Yang M; Jacobsen VA; Takeuchi CS; Macek KJ; Bohacek RS; Dalgarno DC; Weigele M; Lesuisse D; Sawyer TK; Baron R
Bone; 2001 Jan; 28(1):54-64. PubMed ID: 11165943
[TBL] [Abstract][Full Text] [Related]
12. X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor.
Bohacek RS; Dalgarno DC; Hatada M; Jacobsen VA; Lynch BA; Macek KJ; Merry T; Metcalf CA; Narula SS; Sawyer TK; Shakespeare WC; Violette SM; Weigele M
J Med Chem; 2001 Mar; 44(5):660-3. PubMed ID: 11262076
[No Abstract] [Full Text] [Related]
13. SRC inhibitors in metastatic bone disease.
Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716
[TBL] [Abstract][Full Text] [Related]
14. Targeting Src signaling in metastatic bone disease.
Araujo J; Logothetis C
Int J Cancer; 2009 Jan; 124(1):1-6. PubMed ID: 18942061
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Rucci N; Susa M; Teti A
Anticancer Agents Med Chem; 2008 Apr; 8(3):342-9. PubMed ID: 18393792
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening of Src kinase inhibitors.
Lee K; Kim J; Jeong KW; Lee KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Bioorg Med Chem; 2009 Apr; 17(8):3152-61. PubMed ID: 19321350
[TBL] [Abstract][Full Text] [Related]
17. Future anti-catabolic therapeutic targets in bone disease.
Boyce BF; Xing L; Yao Z; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK
Ann N Y Acad Sci; 2006 Apr; 1068():447-57. PubMed ID: 16831942
[TBL] [Abstract][Full Text] [Related]
18. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function.
Horne WC; Sanjay A; Bruzzaniti A; Baron R
Immunol Rev; 2005 Dec; 208():106-25. PubMed ID: 16313344
[TBL] [Abstract][Full Text] [Related]
19. Targeting the SH3 domain of human osteoclast-stimulating factor with rationally designed peptoid inhibitors.
Han S; Liu Q; Wang F; Yuan Z
J Pept Sci; 2016 Aug; 22(8):533-9. PubMed ID: 27443979
[TBL] [Abstract][Full Text] [Related]
20. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
